MindMaze website preview
growth medtech Zurich, CH 3 sources
Own this company? Claim the page to unlock editing and verified-owner badge.

MindMaze develops innovative neurotherapeutic combinations and a treatment ecosystem encompassing behavior, software, devices, and data to transform care for debilitating neurological diseases.

Classification

Zurich CH growth medtech other b2b aiiot NeurotechnologyDigital TherapyRehabNeurological DisordersHealthtech

Profile

Founded
2012
Headcount
unknown
Tech stack
neuro-technology, digital therapeutics, human-machine interfaces
Revenue range
unknown

Funding

Funding details not yet available.

Business model
💡 Value Proposition

A precision neurotherapeutic treatment ecosystem combining behavior, software, devices, and data to redefine brain health and recovery.

👥 Customer Segments

Patients with debilitating neurological diseases and healthcare providers seeking advanced neurotherapeutic interventions.

💰 Revenue Model

Digital therapeutic solutions for neurological diseases, likely involving commercial sales of clinical development pipelines.

📡 Channels

Global commercial growth plans supported by strategic funding rounds to accelerate market expansion.

🤝 Key Partnerships

Investors providing financing for global growth and R&D; likely clinical partners for digital therapeutic validation.

⚖️ Cost Structure

R&D for developing neurotherapeutic combinations, software, and devices within a proprietary treatment ecosystem.

🏗️ Key Resources

Proprietary technology platform, neurotherapeutic data, and expertise in combining behavior, software, and devices.

⚙️ Key Activities

Developing innovative neurotherapeutic combinations and managing a treatment ecosystem for brain health and recovery.

💬 Customer Relationships

Commercial growth focused, leveraging funding to expand reach for neurological treatment solutions.

Strategic analysis
🏁 Competitive landscape

Leaders in neurotherapeutic combinations; differentiates by integrating behavior, software, devices, and data for precision care.

🎯 Market pains

Need for effective care for debilitating neurological diseases and the complexity of managing brain health recovery.

💎 Improvement suggestions
  • Expand payer-centric value propositions - Develop bundled “outcome-as-a-service” contracts that tie reimbursement to specific functional
♟️ Strategic implications
  • Map high-value payer segments (e.g., Medicare Advantage, large employer health plans) and pilot outcome-based contracts within 6 months
🛡️ Credibility notes
  • Clinical validation - Multiple peer-reviewed studies (e.g., PubMed 2025 high-dose gamified rehab trial) demonstrate statistically signifi
Team
Tej Tadi Founder
CEO
Investors

No investors recorded yet.

Sources & references

Web verified · 3 sources
Enriched 18 Jun 2026